Member Info for chester18

Morgan Stanley is a big name to have as a shareholder at this stage of the Parsortix development. They have the resources to do both a deep dive into the data and due diligence into the reality of outcomes from a successful FDA decision.

Where Morgan Stanley invest many will follow.

Fantastic boost for our confidence in the future.

Chester.

Hi StoneRoses

That makes a big difference because I was trying to figure out why the big sells when news was imminent and we are all anticipating Good News..... now that you have explained it takes away that impending cloud of doom...... : (

Also I'm glad that you have been able to keep some stock and be apart of any major rise in the SP.

All my very best

Chester.

Magictrades, thank you for your presentation.

Following on from the last two this presentation was more technical but I was able to really understand how the particular deposits at Havieron and Telfer will potentially differ to Scallywag.

Well done really enjoyed every second of it and now I am more intrigued in the detective story at Scally.

Chester

Hi C7

With the headlines full of the many mutations I would hope LD and team Covidity are pushing as hard as possible to bring their vaccine out of the labs and into early trials. Given that it is also going to be a new delivery system I do hope that it doesn't get to complicated and hold up the entire project.

To put all our minds at ease I'm hopeful that we see a full update on the Covidity Platform when Scancell report the 'Interim Trading Update' at the end of the month.

We've waited a long time for the cancer trials to start and for them to happen we need to clear the pandemic to finally get underway.

all the best

Chester.

Hi FenixDor

I agree that the SP has fallen either on the day or day after each of the Newcrest Quarterly's , but , this time the 10% traders have not been able to hype up the price so unless we see 34p before Wednesdays close I think a good set of core results will actually strengthen the SP this time round .

Even if they just stabilise the sentiment that will do for me.

Chester.

Hi Paddy

As I said I wasn't sure if the Hav cores would also see some delays, I suppose we will have to see what Wednesday night brings. All reported cores should be a continuation of positive reporting just like the last 12 sets.

As per my other question, are there any particular cores that we are waiting for ?
Either a new area or deeper from existing ?

Chester

@ Sre85

I wasn't sure if Newcrest had a large enough lab facility to process all the meterage that is being produced at Havieron. Running 8 rigs 24/7 is a lot of cores to get through. If it is the case that the Telfer labs can cope with that volume then Wednesday won't lead to any further disappointment on reporting delays and that's good to hear.

Thank you for your response

Chester

Normally we be expecting all outstanding drill core results from Newcrest up to the end of December.

Two questions spring to mind :

a) Are there any particular drill cores or part cores that we are hoping to see reported ?
.
b ) Should we expect a much reduced set of reported drill cores due to the type of delays seen with GGP's recent lab based results ?

I am confident that what is reported on Wednesday night will be good but a little concerned about the possible delays in the lab based reports meaning that we see a much reduced number reported.

Chester

Everyone who is invested here wants DNL to do well and as soon as possible.
We just need to find a little more patience as we await reports that the sales are steadily increasing at Eton and that Chronocort passes approval in Europe.

DNL is going to grow as it gains those approvals and more patients are enlightened by their doctors that there are big advantages of moving over to Alkindi and Chronocort.

This will obviously take time especially while we are deep into this worldwide pandemic but importantly there will be a point in the near future when hopefully both of the above have become reality and the company's revenues begin to build quite sharply.

The other reality is that to push Ditest through trials and on to the necessary approvals will take a sizeable chunk of new cash, so the company will have to put forward a plan and explain what finances need to be raised, hopefully at a much SP than today.

DNL is going to grow but it will not be done in the next two or three months. My investment here will be a minimum of 3 - 5 years dependant on quickly that growth is achieved and the ultimate bonus of Ditest showing strong early trial results.

Chester.

Hi Flowkey41 and Enteleon

As advised by 'Ginandmilk' on this board a few days ago the Johnson & Johnson product 'Dermis on Demand' has a footnote acknowledging that the product is manufactured by CellRight which as we know is the company bought by Tissue Regenix.

But what we don't know, is this the new 'White Label Product' or is it just a historic product / supply agreement from several years ago ?

It definitely needs more investigation before we can be absolutely sure.

My initial thoughts were that it would be a tissue repair product to address the controversy of the now repulsive 'Mesh Implant Travesty'.

Really hoping for an 'Interim Trading Update' that also includes the 'White Label' announcement, what we could call a 'Double Tap'............. : )

Chester.

Hi HunSen

I was lucky enough to buy into Greatland Gold when it was still under 2p so that was nice. Other than DNL I think that both Angle (AGL) and Scancell (SCLP) are both sleeping giants, given that they achieve their intended targeted approvals.

Tissue Regenix (TRX) will fly once they start fully using their new production facilities in the USA, news on its commissioning is about to land, and finally Reneuron Group (RENE) are also worth buying as their Stem Cell trials have progressed extremely well in a condition called 'Retinitus Pigmentosa' and they also have the potential to become a manufacturer / developer / supplier of 'Exosomes' platforms which are very much being hailed as the next state of the art 'targeted drug' delivery system, especially because they Exosomes are so small they can cross the blood brain barrier and deliver a very targeted payload.

Hope that gives you enough homework for the weekend ....... : )

Chester.

Hi dsmith57

I thought the same but I think we need to see what the other 4 holes turned up first.
Especially when the cores have not been reported in the order they were drilled in.
My hope is that in those other 4 is the core from Kraken that they Diamond Drilled.

ATB

Chester.

Hi Clivealive

We have seen many changes in sentiment during our investment in Reneuron but like you say it is the science that has always been the main factor. Its barely more than a month since the SP was fleetingly 72.5p and that was straight after the RNS on the Open Offer result dated 11th December. Since then we have had a USA Patent granted, a successful Analyst Conference Call on the 6th of January and the Phase 2a Extension 'Clinical Update' on the 15th.

These three positive news flows have been behind the recent rise.

The nice thing is that we can now look forward to the company reporting as per their published list of inflection points, I know that 'PhilBanks' has already pointed this out a couple of times but here is a quick summary of what is still due in the first quarter 2021 :

1 ) Further Pharma Collaborations !!
2 ) 24 month Read Out of the Phase 2a data **
3 ) RP Ph2a Extension 'First Non-US' patient to be treated ( either in Spain or Oxford ) **
4 ) Proof of Concept data for delivery of siRNA by CTX Derived Exosomes. !!

And there is always a chance that something may be advanced with Fosun Pharma early 2021 but not holding my breathe on that one.

So by the time we reach early April we could have seen an equally large jump in price as per the recent 72.5p to £1.39 in just over one month. Another 50% increase to around £2.50 would be a solid start with much more to come over the whole of 2021.

So not quite £1.50 tomorrow but maybe by the end of February for sure.

All the best

Chester.

Hi zahirmiahoutlook

The share price cannot just move on its own, it either needs positive company news or a major write up by an important or qualified source or a general sentiment changing in the Bio Sector. Any comment on these boards will not create the momentum you require.

So to say £1.50 tomorrow it needs to come with an explanation that shows why you feel so strongly.

I bought into this share when it was between 3p and 6p which in todays money is £3 to £6 and I've bought all the way down to 49p and 78p and 80p. We are not derampers just level headed long term survivors........ : )

Please back up your comments with some argument as to why and we can discuss, that is what these boards are for and why we read them.

All the best with your investments

Chester.

Just realised the RP update is now 24 months, 1st patient treated late January 2019.

" Time fly's when your having " to stay in your house 7 days a week .......... : )

Chester.

Although it's now a well recognised presentation it was another top performance from AN.

Some excellent questions at the end and in fact, far to many to answer in the time allotted so Proactive said they will put up another video with many more questions being answered.

Angle has the potential to be a huge business and will continually build over the next 3 / 5 / 10 years given the FDA clearance.

"Acorns turning into Mighty Oaks"

Chester.

Hi zahirmiahoutlook

As long term holders of Reneuron we have seem multiple times where the share has risen by 50% or more only to drop back from whence it came. Those 'rise and falls' looked very well managed as there wasn't any substantial news to back up the rapid and high percentage increase in the SP.

All that happened was that new investors to RENE bought in at the top and were left high and dry. So unless there is substance to why the price should continue upwards, I like many on here will not be surprised to see the SP back near to £1 without New, Positive News.

But saying all of that a full Ph2 'Retinitus Pigmentosa' 18 months Update plus a strong hint at an Exosomes deal would be very welcome.

All the best

Chester.

Hi jimjam

If you trawl back through the RNS list you will see specific Trading Updates in Feb 19, Oct 19 and Jan 20.
There are none before those that were stated as 'Trading' or 'Interim Business Updates'.
I have seen this many times with other shares so I don't think they have to announce an Interim sets of figures.

The fact that they did in Early 2019 and again in 2020 does not make it a definite. That's how I read the situation, I could be totally wrong.

Chester.

Hi jimjam

So you are a January 'terror' same as me...... lol

TRX don't have to announce an Interim Business Report if they feel they have nothing important or relevant to tell us investors but I think that would not be helpful in the short term.

I'm beginning to think that due to the way the funding was handled back in May there is still a lot of suspicion and a big lack of trust by us PI's, so we are not seeing any speculation buying before the anticipated news.

This is why I see this next Trading Update as a very important starting point on the road to Breakeven and then Trading Profits.

All the best

Chester.

MagicTrades

Excellently explained and pretty honest in your diagnosis of the three drill cores presented yesterday. I'm not a geologist in any way but your walk through of how the geology plays its part in creating the mineralised deposits makes me want to learn more.

Purely from an intrigue point of view, it makes you wonder why we only drilled into the Wilki on two targets and why did GGP pack up early after going back and diamond drilling the the Kraken targets, when they still had a couple of weeks available if wanted.

We will no doubt learn some more once the other 4 cores are released.

Thank you for your brilliantly, ranty video. .......... : )

Chester.